Skip to content

Main Navigation

  • About us
    • History
    • Mission, vision & values
    • Leadership
    • Scientific advisors
    • Our team
    • Social impact (CSR)
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
  • Careers
    • Working with us
    • Open positions
    • Employee stories
  • Events
  • News
  • Contact us
  • LinkedIn

PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space

CPT Pharmacometrics Syst Pharmacol. 2024 Sep 16.
Cloesmeijer ME, Sjögren E, Koopman SF, Lenting PJ, Cnossen MH, Mathôt RAA, OPTI‐CLOT study group and SYMPHONY consortium.
HematologyJournalPBPK/PBBM

Pharmetheus Affiliates

Portrait-of-Erik-Sjogren_Pharmetheus-2
Principal Director, PBPK & PBBM Scientific Lead

Erik Sjögren

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

Contact us

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.